Why Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?

By: via Benzinga
Wednesday,Spruce Biosciences Inc(NASDAQ:SPRB) released topline results from its CAHmelia-203 Phase 2b study of tildacerfont ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.